Renibus Therapeutics Announces Positive Interim Data from RBT-1 Phase 2 Trial Michael Jaramillo2022-10-15T15:56:48-07:00June 15, 2022|
Renibus Therapeutics Expands Leadership Team, Announces Appointments of New Chief Financial Officer and Chief Medical Officer Michael Jaramillo2022-10-15T15:56:54-07:00June 2, 2022|
Renibus Therapeutics Strengthens IP Position with Additional US Patent Michael Jaramillo2022-10-15T15:57:00-07:00April 13, 2022|
Renibus Therapeutics Announces Appointment of Frank Stonebanks as CEO and $35 Million Series A Funding Michael Jaramillo2022-10-15T15:57:06-07:00February 15, 2022|
Renibus Therapeutics Announces Presentations at the American Society of Nephrology Kidney Week 2021 Michael Jaramillo2022-10-15T15:57:11-07:00October 28, 2021|
Rénibus Therapeutics® Initiates Phase 2 Study of RBT-1 for Prevention of Acute Kidney Injury Michael Jaramillo2022-10-15T15:57:16-07:00March 11, 2021|
Rénibus Therapeutics® to Present Phase 1b Data on RBT-1 at Acute Kidney Injury & Continuous Renal Replacement Therapy 2021 Conference Michael Jaramillo2022-10-15T15:57:24-07:00February 25, 2021|
Rénibus Therapeutics® Announces Publication of Positive Results of RBT-3 Experimental Preclinical Studies in Scientific Journal Nephrology Dialysis Transplant Michael Jaramillo2022-10-15T15:57:30-07:00February 16, 2021|
Presentations at the American Society of Nephrology Kidney Week 2020 Michael Jaramillo2022-10-15T15:57:36-07:00October 19, 2020|
Renibus Therapeutics® Announces Abstract Presentation at the 2020 European Renal Association – European Dialysis and Transplant Association (ERA-EDTA) Annual Congress Dallas, June 09, 2020 (GLOBE NEWSWIRE) — Renibus [...] Michael Jaramillo2022-10-15T16:11:58-07:00June 9, 2020|